Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

Presentation TCT Abstracts Posters 2019

Impact of Calcified Plaque Angulation on Clinical Outcomes Following Bioresorbable Vascular Scaffold Implantation: Insights from ABSORB III and ABSORB Japan

Presenter: Shinji Imura

September 29, 2019

Presentation TCT 2019

The Post-Absorb BVS Era: Lessons Learned and Implications for Trial Design and Device Approval

Presenter: Andrew Farb

September 28, 2019

Presentation TCT 2019

The Absorb BVS Epilogue: How Did We Miss the Safety Signals?

Presenter: Renu Virmani

September 28, 2019

Presentation TCT 2019

TCT 48: Bioresorbable Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis (COMPARE-ABSORB trial) : Very late device thrombosis while on extended DAPT

Presenter: Robert-Jan Van Geuns

September 25, 2019

Presentation TCT 2019

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

Presenter: Run-Lin Gao

September 25, 2019

Presentation

Myocardial Blood Flow and Coronary Flow Reserve 3 Years After Absorb BVS vs DES: VANISH

April 30, 2019

News Daily News

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

Michael O'Riordan

April 30, 2019

Advertisement

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

Impact of Calcified Plaque Angulation on Clinical Outcomes Following Bioresorbable Vascular Scaffold Implantation: Insights from ABSORB III and ABSORB Japan

The Post-Absorb BVS Era: Lessons Learned and Implications for Trial Design and Device Approval

The Absorb BVS Epilogue: How Did We Miss the Safety Signals?

TCT 48: Bioresorbable Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis (COMPARE-ABSORB trial) : Very late device thrombosis while on extended DAPT

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

Myocardial Blood Flow and Coronary Flow Reserve 3 Years After Absorb BVS vs DES: VANISH

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content